exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
BlueRock Therapeutics LP
Start Date
November 4, 2025
End Date
December 31, 2032
Administered By
Neurology, Movement Disorders
Awarded By
BlueRock Therapeutics LP
Start Date
November 4, 2025
End Date
December 31, 2032